Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Novartis : Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Novartis's AFINITOR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 10:25am CEST

Release date- 02102017 - NEW YORK - The U.S. Patent & Trademark Office (PTO) on September 25, 2017 granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the last-expiring patent listed as covering Novartis Pharmaceuticals' AFINITOR (everolimus tablet) drug in the Food & Drug Administration's Orange Book.

Argentum challenges claims 13 of Novartis's U.S. Patent No. 9,006,224, which the Orange Book states will expire in 2028. The PTO concluded that Argentum has established a 'reasonable likelihood that [Argentum] would prevail with respect to claims 1-3' of the patent. The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board. A final decision on patentability in the IPR is due within 1 year.

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.

Contact:

Email: http://www.argentumpharmaceuticals.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
02:42pNOVARTIS : to file for new Lucentis® (ranibizumab) indication in retinopathy of ..
AQ
02:37pNOVARTIS : New analysis of Novartis Phase III brolucizumab (RTH258) data reinfor..
AQ
01:17pSPARK THERAPEUTICS : Novartis Announces Positive CHMP Opinion for One-Time Gene ..
AQ
12:45pSPARK THERAPEUTICS : Novartis Luxturna approved to treat rare retinal disease
AQ
12:45pSPARK THERAPEUTICS : Novartis announces positive CHMP opinion for one-time gene ..
AQ
10:44aSPARK THERAPEUTICS : Novartis drums up EU launch plans as CHMP gives thumbs up t..
AQ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
09/21NOVARTIS : uBiome moving into therapeutics with $83M series C
AQ
09/21Triple Set of EMA Recommendations for Novartis Drugs
DJ
09/21NOVARTIS : Sandoz receives positive CHMP opinion for proposed biosimilar pegfilg..
GL
More news
News from SeekingAlpha
09/21Sutro Biopharma Prepares Terms For $75 Million U.S. IPO 
09/21New opinions from EMA advisor CHMP 
09/21YOUR DAILY SCOOP : Unum's Positive Data, Theravance's Treatment Benefit, Collect.. 
09/21Breaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is I.. 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
Financials ($)
Sales 2018 52 459 M
EBIT 2018 12 888 M
Net income 2018 11 683 M
Debt 2018 14 565 M
Yield 2018 3,46%
P/E ratio 2018 14,72
P/E ratio 2019 20,91
EV / Sales 2018 4,40x
EV / Sales 2019 4,24x
Capitalization 216 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 91,5 $
Spread / Average Target 7,0%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-0.63%216 108
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092
AMGEN17.94%132 756